Jci_page_head_homepage_01 Jci_page_head_homepage_02
Irini Bournazou, John D. Pound, Rodger Duffin, Stylianos Bournazos, Lynsey A. Melville, Simon B. Brown, Adriano G. Rossi, Christopher D. Gregory
Published in Volume 119, Issue 1
J Clin Invest. 2009; 119(1):20–32 doi:10.1172/JCI36226
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 3
Lactoferrin specifically inhibits neutrophil chemotaxis.

Neutrophil chemotaxis in the presence of human anti-lactoferrin (anti-LTF) polyclonal antibody (gray) or isotype control (black) using conditioned media from BL (A) and MCF7 (B) cells (A: n = 3, *P < 0.05 vs. isotype control, NS vs. fMLP anti-lactoferrin control; B; n = 3, P < 0.001 vs. fMLP/isotype; NS vs. fMLP/anti-LTF. (C) RT-PCR analysis to assess lactoferrin expression in BL cells stably expressing LTF shRNA (LTF) cells and mock-transfected (mm) cells induced to become apoptotic (1 μM staurosporine; 37°C). (D) Chemotaxis assay to determine neutrophil migration toward supernatants obtained from control, LTF shRNA, and mock-transfected BL cells (n = 5; §P < 0.05 compared with mm shRNA control; **P < 0.05 compared with fMLP; NS compared with fMLP control). (E) Dose-response analysis of purified human lactoferrin. n = 3; P < 0.05 vs. 0 g/ml purified LTF + fMLP. Error bars indicate SEM.